Aunan Greg D 4
4 · NEOGENOMICS INC · Filed Feb 24, 2026
Research Summary
AI-generated summary of this filing
NeoGenomics (NEO) Chief Accounting Officer Greg Aunan Receives 6,323 Shares
What Happened Greg D. Aunan, Chief Accounting Officer of NeoGenomics (NEO), had 6,323 restricted stock units convert into 6,323 shares on February 21, 2026 (reported on Form 4 filed Feb 24, 2026). The company withheld 1,875 of those shares to satisfy tax withholding obligations, resulting in a net increase of 4,448 shares to his holdings. The transactions are recorded with transaction codes M (exercise/conversion of a derivative) and F (payment of exercise price or tax withholding); price reported is $0.00 per share, consistent with RSU settlement rather than a cash buy.
Key Details
- Transaction date(s): February 21, 2026; Form 4 filed February 24, 2026.
- Reported prices: $0.00 per share (RSU conversion/settlement).
- Shares issued on vesting: 6,323; shares withheld for taxes: 1,875; net shares to insider: 4,448.
- Shares owned after transaction: Not disclosed in the provided excerpt.
- Relevant footnotes:
- F1: Each RSU equals one share and converts on vesting.
- F2: 1,875-share disposition was withholding to satisfy tax obligations on RSU release.
- F3–F8: Background on prior RSU and option grants and their vesting schedules.
- Filing timeliness: Filed 3 days after the transaction date per the provided dates; no late-filing indicator was included in the excerpt you provided.
Context This was an issuance on vesting of equity awards (RSUs), not an open-market purchase or an outright sale. Withholding shares to cover taxes is a routine administrative step and does not necessarily signal a change in the insider’s view of the company. The $0.00 exercise price and the footnotes indicate these shares resulted from previously granted awards that vest over time.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-02-21+6,323→ 23,902 total - Tax Payment
Common Stock
[F2]2026-02-21−1,875→ 22,027 total - Exercise/Conversion
Restricted Stock Unit
[F3][F4]2026-02-21−6,323→ 12,648 totalExercise: $0.00→ Common Stock (6,323 underlying)
- 28,662
Stock Option (Right to Buy)
[F5]Exercise: $14.62Exp: 2030-05-01→ Common Stock (28,662 underlying) - 26,978
Stock Option (Right to Buy)
[F6]Exercise: $13.96Exp: 2034-05-02→ Common Stock (26,978 underlying) - 16,117
Restricted Stock Unit
[F7][F4]Exercise: $0.00→ Common Stock (16,117 underlying) - 31,163
Stock Option (Right to Buy)
[F8]Exercise: $11.86Exp: 2035-02-21→ Common Stock (31,163 underlying)
Footnotes (8)
- [F1]Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting.
- [F2]Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
- [F3]On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F4]Once vested, the shares of common stock are not subject to expiration.
- [F5]On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
- [F6]On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
- [F7]On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
- [F8]On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.